A
ARVN
Arvinas
9.24
-0.08-0.86%After Hours: 9.24 0.00 0.00%19:42 08/27 EDT
OPEN/PREV CLOSE9.27/9.32
TODAY RANGE9.15-9.43
VOL527.01K
MARKET CAP604.17M
52 WEEK RANGE6.97-14.51
AVG VOL (3M)786.78K
% TURNOVER0.81%
TURNOVER--
P/E (TTM)57.61
% RANGE3.00%
EPS(TTM)0.1604
P/E(FORWARD)725.84
P/B1.073
BVPS8.61
DIVIDEND--
P/S2.234
BETA--
DIV YIELD0.00%
FREE FLOAT MKT CAP556.99M
SHARES OUTSTANDING65.39M
NEXT EARNINGS11/03-11/09
FREE FLOAT60.28M
LOT SIZE1
EX-DATE--
News
Press Releases
Financial Reports
Profile
Dow Jones·08/10 16:28
Arvinas Is Maintained at Outperform by Evercore ISI Group
Dow Jones·08/10 16:28
Arvinas Price Target Cut to $14.00/Share From $19.00 by Evercore ISI Group
Benzinga·08/10 16:17
Evercore ISI Group Maintains Outperform on Arvinas, Lowers Price Target to $14
Dow Jones·08/10 15:24
Arvinas Price Target Cut to $21.00/Share From $24.00 by Citigroup
Dow Jones·08/10 15:24
Arvinas Is Maintained at Buy by Citigroup
Benzinga·08/10 15:14
Citigroup Maintains Buy on Arvinas, Lowers Price Target to $21
TipRanks·08/10 12:35
Truist Financial Releases a Hold Rating on Arvinas Holding Company (ARVN)
TipRanks·08/10 12:27
Arvinas price target lowered to $10 from $11 at Morgan Stanley
TipRanks·08/10 10:55
Citi Reaffirms Their Buy Rating on Arvinas Holding Company (ARVN)
TipRanks·08/06 16:41
Arvinas Launches New Cancer Combo Trial, Adding Fresh Optionality to ARVN
NASDAQ·08/06 16:00
Arvinas (ARVN) Upgraded to Strong Buy: Here's What You Should Know
Seeking Alpha·08/06 02:10
Rigel Pharmaceuticals: A Four-Drug Company With A Clinical Catalyst Ahead
Same Industry
Name/Symbol
Change%
Price